<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="152050">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01120639</url>
  </required_header>
  <id_info>
    <org_study_id>BRN0012</org_study_id>
    <secondary_id>SU-04202010-5726</secondary_id>
    <secondary_id>17774</secondary_id>
    <nct_id>NCT01120639</nct_id>
  </id_info>
  <brief_title>PI/II of Temozolomide &amp; Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform</brief_title>
  <official_title>A Phase I/II Trial of Temozolomide and Hypofractionated Radiotherapy in Treatment of Supratentorial Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and effectiveness of a combination
      treatment for glioblastoma multiforme utilizing radiotherapy with the FDA approved
      chemotherapy drug temozolomide
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine the maximum tolerated dose (MTD) of hypofractionated (5 fractions) radiotherapy
      with temozolomide for the treatment of glioblastoma multiforme, patients will be evaluated
      by a multi-disciplinary team composed of radiation oncologists, neurosurgeons, and
      neuro-oncologists to assess for their eligibility. Patient's oncologic history, presenting
      symptoms, physical examination, pathology, and imaging studies will be reviewed. Patients
      will be evaluated for surgical candidacy and resectability. Patients who are surgical
      candidates will undergo a surgical resection prior to radiotherapy. Patients whose tumors
      are unresectable or are not good surgical candidates will undergo a biopsy for tissue
      diagnosis. Radiation will be delivered in five fractions.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the maximum tolerated dose (MTD) of hypofractionated radiotherapy given in 5 fractions with temozolomide for the treatment of glioblastoma multiforme</measure>
    <time_frame>Duration of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the progression-free survival rate.</measure>
    <time_frame>Duration of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the short- and long-term adverse effects.</measure>
    <time_frame>Duration of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the radiographic response rate.</measure>
    <time_frame>Duration of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the overall survival rate.</measure>
    <time_frame>Duration of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perform patterns of failure analysis.</measure>
    <time_frame>Duration of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess quality of life during treatment.</measure>
    <time_frame>Duration of study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Glioblastoma</condition>
  <condition>Cancer of Brain and Nervous System</condition>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>PTV (Planning Target Volume) &lt; 60 cm3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide
Dose Levels:
25 Gy in 5 fractions
30 Gy in 5 fractions
35 Gy in 5 fractions
40 Gy in 5 fractions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Planning Target Volume of 60 to 150 cm3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide
Dose Levels:
25 Gy in 5 fractions
30 Gy in 5 fractions
35 Gy in 5 fractions
40 Gy in 5 fractions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>75 mg/m2/day, oral</description>
    <arm_group_label>PTV (Planning Target Volume) &lt; 60 cm3</arm_group_label>
    <arm_group_label>Planning Target Volume of 60 to 150 cm3</arm_group_label>
    <other_name>Temodar</other_name>
    <other_name>Temodal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stereotactic Radiosurgery</intervention_name>
    <description>Standard of care</description>
    <arm_group_label>PTV (Planning Target Volume) &lt; 60 cm3</arm_group_label>
    <arm_group_label>Planning Target Volume of 60 to 150 cm3</arm_group_label>
    <other_name>Cyberknife surgery</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histopathologically confirmed newly diagnosed glioblastoma multiforme. Diagnosis must
             be made by surgical biopsy or excision

          -  The tumor must be supratentorial in location

          -  The planning target volume (tumor plus margin) must measure &lt;= 150 cm^3 in volume

          -  Age &gt;=18 years

          -  Life expectancy of at least 12 weeks

          -  Patient must have adequate organ function to tolerate temozolomide (details in the
             protocol)

        Exclusion Criteria:

          -  Patients who have previously been treated with brain irradiation to the region that
             would result in overlap of the radiation fields

          -  Tumor foci detected below the tentorium

          -  Multifocal disease or leptomeningeal spread

          -  Prior allergic reaction to the study drugs involved in this protocol

          -  Patients with pacemaker will be allowed to undergo CT instead of MRI

          -  Pediatric patients (age &lt;18), pregnant women, and nursing patients will be excluded
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Soltys</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 5, 2017</lastchanged_date>
  <firstreceived_date>May 7, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Scott Soltys</investigator_full_name>
    <investigator_title>Assistant Professor of Radiation Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
